In a cohort of 433 patients with IDH1-mutated grade 2–3 gliomas (34), approximately 9.9% had non-canonical mutations, and presented with younger age at diagnosis and favorable prognosis (198.6 months vs. 138.5 months; p < 0.05). The gene discussed is IDH1; the disease is central nervous system cancer.